Clinical Trials: Improving Care of Women with Breast Cancer Through Research
|
|
- Alexia Elliott
- 5 years ago
- Views:
Transcription
1 Clinical Trials: Improving Care of Women with Breast Cancer Through Research Som Mukherjee MD, MSc, FRCP(C) Life After Breast Cancer October 17, 2013
2 Breast Cancer
3 Is research making a difference?
4 Waging the war against cancer
5 Questions to answer today What is a clinical trial? How has research in breast cancer helped us get to where we are today? What are the pros and cons of joining a clinical trial? Breast cancer trials at the Juravinski Cancer Centre: is there a study out there that can help me? What does the future hold for breast cancer research?
6 Why is cancer such a difficult disease to cure?
7 Inside the Breast Cancer Cell
8 How did we get here? A Brief History of Breast Cancer Research
9 Earliest research 1600 B.C. Ancient Egypt Several cases of ulcerous tumours of the breast It was written that there is no treatment
10 A Brief History In the 1700 s, it was commonly thought that breast cancer was caused by: too little sexual activity too much sexual activity trauma to the breast clothing that was too tight
11 History of Breast Cancer Breast cancer was not as common until 1800 s, when infectious diseases were better controlled, sanitation improved and lifespan started to increase dramatically At that time, surgery had a high mortality rate
12 Life Expectancy
13 Age and Risk of Breast Cancer Age in 203 women Age 40 to 59 1 in 27 women Age 60 to 69 1 in 28 women Age 70 and older 1 in 15 women
14 Breast Cancer Research Surgery Dr. Halstead ( ) published research on the radical mastectomy and this dramatically improved mortality rates in breast cancer Modified radical mastectomy Lumpectomy and radiation vs. mastectomy
15 Breast Cancer Research: Hormonal Therapy Sir George Beaton, Scottish Surgeon discovered the link between breast cancer and hormones Published 3 cases of women with breast cancer which shrunk dramatically after removal of their ovaries, which was performed for other reasons
16 Breast Cancer Research - Chemotherapy 1960 s Dr. Fisher and Dr. Bonnadonna discovered that chemotherapy given after surgery improved the cure rate for breast cancer patients anthracyclines (doxorubicin, adriamycin) 1987 paclitaxel found to be effective (Taxol) 2000 s Hamilton-led trials: MA-5, Dr. Mark Levine et al CEF vs. CMF MA-21, Dr. Mark Levine et al CEF, AC/T, dose dense EC/T
17 Back to the present: Clinical Trials at the JCC
18 What is a Clinical Trial? A clinical trial is a type of research that uses human volunteers (also called participants) and is intended to add to medical knowledge Clinical trials allow patients the possibility to receive a new type of treatment or test
19 Types of Research at the JCC
20 Clinical Trials at the JCC The Clinical Trials Department at JCC is one of the largest in Canada Oncologists recruit patients to over 70 different clinical trials at JCC every year Many breast cancer clinical trials currently open at JCC
21 Recent JCC Clinical Trials in Breast Cancer
22 1. Radiation Trials Dr. Tim Whelan Radiation trials looking at fewer number of treatments following surgery for breast cancer 16 treatments equivalent to 25 treatments for women with early stage breast cancer following lumpectomy this has impacted on treatment across the world Looking at trying to determine if 5 days of treatment suitable for certain patients
23 2. HERA Trial CANADA 71.5% NORDIC COUNTRIES EU EASTERN EUROPE: 11% JAPAN CENTRAL & SOUTH AMERICA 5.5% 12% ASIA PACIFIC SOUTH AFRICA AUSTRALIA NEW ZEALAND
24 Herceptin
25 HERA Trial Women who received chemotherapy after surgery were randomized to receive no Herceptin (trastuzumab) or 1 year of Herceptin or 2 years of Herceptin Results presented in 2006 showed that 1 year of Herceptin was better than no Herceptin (recurrence rate almost half at 2 years) Cure rates for HER2 +ve breast cancer have improved significantly (24% decrease) since the arrival of Herceptin
26 Insulin and Cancer
27 3. MA-32: Metformin in Breast Cancer New research suggests that insulin helps to increase the ability of cancer cells to grow, divide and spread Clinical trial of metformin in breast cancer has completed accrual Preliminary results presented at ASCO 2013 showed that metformin resulted in weight loss, improved glucose levels and lower insulin levels Awaiting results of data looking at breast cancer recurrence rates
28 4. LISA Trial Randomized controlled trial evaluating the usefulness of a telephone-based lifestyle intervention vs. written material Results presented at ASCO 2013 Showed that significant weight loss was seen after 6, 12 and 18 months of a lifestyle intervention
29 5. Hamilton led MA-21 trial Women with high risk breast cancer randomized to one of 3 treatment groups: AC/T every 3 weeks Dose dense EC/T CEF chemotherapy Results showed that AC/T given every 3 weeks was not as effective as the other 2 regimens
30 6. Oncotype Dx Trials Oncotype Dx is a new tool that helps oncologists determine if a patient might benefit from adjuvant chemotherapy (following surgery) McMaster University/JCC are leading this study through the Ontario Clinical Oncology Group to determine how often this test changes treatment plans in patients
31 Hope for the Future Knowledge gained from clinical trials has led the way and improved the treatment of breast cancer Generations of patients before us have helped us figure out how best to treat our patients Research gives us all hope
32 Working Together Worldwide Worldwide movement of research Conferences sharing research: CAMO, ASCO, ESMO
33 Are we making progress in breast cancer?
34 Better Prevention
35 Improved Diagnosis
36 Better Treatments Surgery Radiation
37 Better Treatments New breast cancer drugs approved by Health Canada over past 10 years: Herceptin (trastuzumab) and lapatinib (Tykerb) for HER2 +ve breast cancer T-DM1, pertuzumab Hormonal therapies aromatase inhibitors (letrozole (Femara), anastrazole (Arimidex), exemestane (Aromasin) Everolimus (Afinitor) Chemotherapy eribulin Bone agents denosumab, pamidronate
38 What about me? Why Should I Participate in Clinical Trials? Possibility that you could benefit yourself from new treatments Opportunity to help other patients in the future Increase global understanding of breast cancer
39 Active Breast Cancer Trials at the JCC Click on Clinical Trials
40 Journey Story on the battle against cancer not over yet Final chapter has yet to be written Our understanding of cancer has increased dramatically over the past 50 years and continues to increase on a daily basis
41 My Vision for the Future
42 Clinical trials are the vital link between breakthroughs in the lab and new treatments that extend and improve patients lives
43 The Real Heroes of Research (you!)
44
45 Thank You!
Adjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationSystemic Treatment of Breast Cancer. Hormone Therapy and Chemotherapy, Curative and Palliative
Systemic Treatment of Breast Cancer Hormone Therapy and Chemotherapy, Curative and Palliative Systemic Therapy Invasive breast cancers Two forms Curative Palliative Curative Systemic Therapy Adjuvant Therapy
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationEvolving Practices in Breast Cancer Management
Evolving Practices in Breast Cancer Management The Georgia Tumor Registrars Association 2016 Priscilla R. Strom, MD, FACS Objectives 1. understand newer indications for neoadjuvant treatment 2. understand
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationBreast cancer remains the most common malignancy and the second leading. cause of cancer mortality in women in the United States.
Dr. Andrew Seidman s Commentary I. Breast Cancer Overview Breast cancer remains the most common malignancy and the second leading cause of cancer mortality in women in the United States. The following
More information4/13/2010. Silverman, Buchanan Breast, 2003
Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk
More informationUpdate from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002
Update from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002 Nearly 5,000 physicians, oncologists, radiologists, epidemiologists, basic scientists, and breast cancer advocates from
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment
More informationBeyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer
Beyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer Wednesday, December 11, 2013 7:30 PM 9:30 PM San Antonio,
More informationIdeal neo-adjuvant Chemotherapy in breast ca. Dr Khanyile Department of Medical Oncology, University of Pretoria
Ideal neo-adjuvant Chemotherapy in breast ca Dr Khanyile Department of Medical Oncology, University of Pretoria When is neo-adjuvant Chemo required? Locally advanced breast ca: - Breast conservative surgery
More informationBreast Cancer Treatment
Breast Cancer Treatment Treatment 2 aspects 1. Treatment of the breast itself: Local Treatment 2. Treatment of the whole body = Systemic treatment Local Treatment Surgery +/- Radiation Usually: a. Breast
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationLatest News in Breast Cancer Research
Latest News in Breast Cancer Research Highlights from the 2011 San Antonio Breast Cancer Symposium www.cancercare.org This special edition of the CancerCare Connect booklet series highlights cutting-edge
More informationWhat is the Oncotype DX test?
Patient & Family Guide 2018 What is the Oncotype DX test? www.nscancercare.ca What is the Oncotype DX test? Information for women diagnosed with early-stage breast cancer What is the Oncotype DX test?
More informationKey Words. Adjuvant therapy Breast cancer Taxanes Anthracyclines
The Oncologist Mayo Clinic Hematology/Oncology Reviews Adjuvant Therapy for Breast Cancer: Recommendations for Management Based on Consensus Review and Recent Clinical Trials BETTY A. MINCEY, a,b FRANCES
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More informationSystemic Management of Breast Cancer
Systemic Management of Breast Cancer Why Who When What How long Etc. Vernon Harvey Rotorua, June 2014 Systemic Management of Breast Cancer Metastatic Disease Adjuvant Therapy Aims of therapy Quality of
More informationThe worldwide overview: updated (2005-6) meta-analyses of hormonal treatment trials
The worldwide overview: updated (2005-6) meta-analyses of hormonal treatment trials Richard Gray, for the Early Breast Cancer Trialists Collaborative Group (EBCTCG) Main questions, 2005-6 1) 5 years of
More informationUpdate from the 29th Annual San Antonio Breast Cancer Symposium
Update from the 29th Annual San Antonio Breast Cancer Symposium The San Antonio Breast Cancer Symposium is one of the most important breast cancer conferences. Approximately 8,000 physicians, oncologists,
More informationChapter. Contents Breast Cancer Adjuvant Epirubicin weekly. Docetaxel Copy No:
Chapter 2: Breast Cancer Contents Chapter 2: Breast Cancer... 1 Breast Cancer... 2 Adjuvant...... 2 Epi-CMF... 2 FEC / docetaxel... 3 FEC100... 4 AC/EC/TC... 4 (neo) adjuvant... 5... 5 HER2 positive: TCarboH...
More informationHighlights from the 2009 Annual Meeting of the American Society of Clinical Oncology
BREAST CANCER 24 Breast Cancer Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by William J. Gradishar, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern
More informationBeyond the Break. After Breast Cancer: Osteoporosis in Survivorship. Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO
Beyond the Break After Breast Cancer: Osteoporosis in Survivorship Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO Disclosures No disclosures Osteoporosis in Breast Cancer Survivorship
More informationTRANSPARENCY COMMITTEE OPINION. 15 February 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial
More informationToxicities of Chemotherapy Regimens used in Early Breast Cancer
Toxicities of Chemotherapy Regimens used in Early Breast Cancer CERCIT Workshop February 17, 2012 Carlos H Barcenas, M.D., M.S. Fellow Hematology-Oncology MD Anderson Cancer Center CERCIT Scholar Outline
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen
More informationGASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS HLC174A October 2015 Usha Nagavarapu Project Analyst ISBN: 1-62296-167-6 BCC Research 49 Walnut Park, Building 2 Wellesley,
More informationUnderstanding Tumor Markers for Breast and Colorectal Cancers. A Patient s Guide. Recommendations of the American Society of Clinical Oncology
Cover Layout 1 A Patient s Guide Understanding Tumor Markers for Breast and Colorectal Cancers Recommendations of the American Society of Clinical Oncology ... Cover Layout 2 A Patient s Guide Understanding
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationDr. Som Mukherjee MD, MSc, FRCP(C) Juravinski Cancer Centre October 19, 2011
Dr. Som Mukherjee MD, MSc, FRCP(C) Juravinski Cancer Centre October 19, 2011 Plan of Action Chemotherapy related cognitive dysfunction Peripheral neuropathy Weight gain Early menopause Chemo Brain A problem
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More informationBreast Cancer Scanning the Horizon
Breast Cancer Scanning the Horizon Prof Fran Boyle BCNA Summit Sydney 2013 Feature Interview: Dr Fran Boyle :: Sunday Nights - ABC www.abc.net.au/sundaynights/stories/s1544975.htm Familial breast cancer
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationAmerican Society of Clinical Oncology June , New Orleans
American Society of Clinical Oncology June 5-8 2004, New Orleans The 2004 annual meeting of the American Society of Clinical Oncology (ASCO) was held June 5 8 in New Orleans, Louisiana. This conference
More informationChapter 5: Epidemiology of MBC Challenges with Population-Based Statistics
Chapter 5: Epidemiology of MBC Challenges with Population-Based Statistics Musa Mayer 1 1 AdvancedBC.org, Abstract To advocate most effectively for a population of patients, they must be accurately described
More informationInvasive Breast Cancer
Invasive Breast Cancer Eileen Rakovitch MD MSc FRCPC Sunnybrook Health Sciences Centre Medical Director, Louise Temerty Breast Cancer Centre LC Campbell Chair in Breast Cancer Research Associate Professor,
More informationDoes HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey
MYERS et al. ORIGINAL ARTICLE Does HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey J.A. Myers MD FRCPC, G.
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationAppendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
More informationFDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE NODE-POSITIVE BREAST CANCER
NEWS RELEASE Media Contact: Kimberly Ocampo (650) 467-0679 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Ajanta Horan (650) 467-1741 FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF
More informationJules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast International Group (BIG aisbl), Chair ESMO President
Symposium «Evaluation of the Belgian Cancer Plan» Brussels, November 26th, 2012 Personalized oncology in Europe: only a dream if national health systems do not get involved in diagnostics and pivotal cancer
More informationClinical Policy: Lapatinib (Tykerb) Reference Number: CP.PHAR.79 Effective Date: Last Review Date: 11.17
Clinical Policy: (Tykerb) Reference Number: CP.PHAR.79 Effective Date: 10.01.11 Last Review Date: 11.17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More informationEuropean consortium study on the availability of anti-neoplastic medicines
European consortium study on the availability of anti-neoplastic medicines Nathan I Cherny Alexandru ENIU, MD, PhD Norman Levan Chair in Humanistic Chair, Emerging Countries Committee Medicine Department
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationHormonal Therapies for Breast Cancer. Westmead Breast Cancer Institute
Hormonal Therapies for Breast Cancer Westmead Breast Cancer Institute Hormonal (endocrine) therapies for breast cancer (also called anti-hormone treatment ) Hormonal therapy is used to treat breast cancers
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationA Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer
A Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer Dr. Susan Ellard Surgical Oncology Update October 24, 2009 Disclosure slide Participant in various meetings or advisory boards sponsored by
More informationHealthcare Cost-Effectiveness Analysis for Older Patients: Using Cataract Surgery and Breast Cancer Treatment Data. Chapter 5
Healthcare Cost-Effectiveness Analysis for Older Patients: Using Cataract Surgery and Breast Cancer Treatment Data Chapter 5 Decision Analysis Modeling of the Adjuvant Treatment of Older Patients with
More informationBreastCancerAdvisor by DR. SILVANA MARTINO January 2014
BreastCancerAdvisor by DR. SILVANA MARTINO January 2014 Dear Readers, It is the start of a new year and even as I get a bit older, I still experience great joy at this time. A feeling that there is a new
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationMedia Release. FDA grants Roche s Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer
Media Release Basel, 1 October 2013 FDA grants Roche s Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer The Perjeta regimen is the first treatment
More informationOUTLINE PAST PRESENTFUTURE BREAST CANCER INCIDENCE AND MORTALITY CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM
OUTLINE CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM October 11, 2014 SARA M GARRIDO, M.D., F.A.C.P Chief Medical Officer at AMS Miami, October 11, 2014 PAST PRESENTFUTURE -BRIEF
More informationEducator Navigation Guide
Decoding Breast Cancer Virtual Lab Educator Navigation Guide Decoding Cancer Nav Guide 2 Introduction In this virtual lab, students test tissue samples from different patients with breast cancer in order
More informationBreast Cancer. Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology
Breast Cancer Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology ABOUT ASCO Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO ) is committed
More informationLessons Learnt from Neoadjuvant Hormone Therapy. 10 Lessons Learnt from Neoadjuvant Endocrine Therapy. Lesson 1
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationLessons Learnt from Neoadjuvant Hormone Therapy. Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationHorizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887
Horizon Scanning Centre November 2012 Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887 This briefing is based on information available at the time of research and a
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Trastuzumab, as monotherapy and in combination with a taxane, for the treatment of metastatic breast cancer (to include
More informationThe Three Ages of Systemic Adjuvant Therapy for EBC
The Three Ages of Systemic Adjuvant Therapy for EBC 1896-2018 Nicholas Wilcken Westmead Hospital Petersham Institute University of Sydney Questions to be answered (concentrating on chemotherapy) Why should
More informationBreast Cancer Treatment, Outcomes and Recent Advances. Ogori N Kalu, MD, MS Director Breast Surgery-UH Asst. Prof of Surgery Rutgers NJ Med School
Breast Cancer Treatment, Outcomes and Recent Advances Ogori N Kalu, MD, MS Director Breast Surgery-UH Asst. Prof of Surgery Rutgers NJ Med School National Statistics 1 in 8 women in the U.S. (12-13%) will
More informationDEFINITION. Breast cancer is cancer that forms in the. more common in women.
BREAST CANCER DEFINITION Breast cancer is cancer that forms in the cells of the breasts. Breast cancer can occur in both men and women, but it's far more common in women. Normal Breast Tissue DEFINITION
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationCancer Care Ontario Practice Guidelines Initiative Sponsored By: Cancer Care Ontario & the Ministry of Health and Long-term Care
Cancer Care Ontario Practice Guidelines Initiative Sponsored By: Cancer Care Ontario & the Ministry of Health and Long-term Care Adjuvant Systemic Therapy for Node-negative Breast Cancer ORIGINAL GUIDELINE:
More informationBreast cancer. Prof Arlene Chan Medical Oncologist Director Breast Clinical Trials Unit, Mount Hospital Vice-Chair Breast Cancer Research Centre - WA
Breast cancer rof Arlene Chan Medical Oncologist Director Breast Clinical Trials Unit, Mount Hospital Vice-Chair Breast Cancer Research Centre - WA Breast cancer Incidence of Breast Cancer by Stage at
More informationMedia Release. Basel, 3 June 2012
Media Release Basel, 3 June 2012 Roche s targeted investigational breast cancer medicine, trastuzumab emtansine (T-DM1), reduced the risk of cancer worsening or death by 35 percent in pivotal phase III
More informationA Guide for Women with Breast Cancer
INFORMATION SHEET The sheet has information about diagnosis, treatment, practical support and the emotional impact of breast cancer. We hope this information sheet will answer some of your questions and
More informationRoche s Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer
Media Release Basel, 31 July, 2015 Roche s Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer The approval is based on the benefit seen with the Perjeta regimen
More informationBreast Cancer. Controversies in the Therapy of Early Stage Breast Cancer. The Oncologist 2005;10:
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Breast Cancer Controversies in the Therapy of Early Stage Breast
More informationThe HERA Study Team. Presented by Ian E. Smith
Trastuzumab Following Adjuvant Chemotherapy in HER2-Positive Early Breast Cancer (HERA Trial): Disease-Free and Overall Survival after 2 Year Median Follow-Up The HERA Study Team Presented by Ian E. Smith
More informationAdvances in Neoadjuvant and Adjuvant Therapy for Breast Cancer
Advances in Neo and Adjuvant Therapy for Breast Cancer Nicole Kounalakis, MD, and Christina Finlayson, MD OVERVIEW Systemic therapy for breast cancer is evolving rapidly. The medical treatment of cancer
More informationClinical Policy: Pertuzumab (Perjeta) Reference Number: CP.PHAR.227 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Perjeta) Reference Number: CP.PHAR.227 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the
More informationBreast Cancer & Personalized Medicine
Principles of Drug Development and Discovery Breast Cancer & Personalized Medicine Grace Leung, Efrat Shalom-Berensohn, Felipe Castro, Kate Burke-Wallace and Shiv Gaglani Breast Cancer... 2 nd most common
More informationA breast lump or thickening that feels different from the surrounding tissue
Breast Cancer Breast cancer is caused by abnormal cells that form in the breast tissue. Breast cancer is the most common cancer affecting South African women 1 in 35 women in South Africa will be diagnosed
More information/ NCCN. ACS (www.cancer.org) NCC (www.nccn.org) NCCN NCCN ACS ACS-2345
/2002 9 /2002 9 (NCCN) (ACS) NCCN ACS (www.cancer.org) NCC (www.nccn.org) NCCN 1-888-909-NCCN ACS 1-800-ACS-2345 NCCN ACS NCCN NCCN ACS NCCN 2002 (NCCN) (ACS) NCCN ACS ...................................
More informationStandard Breast Cancer Therapy
Pt s Who Don t Follow Treatment Standard Breast Cancer Therapy Deborah Thames R.T. (R)(M)(QM) Advancements in Breast Cancer Advancements in Breast Cancer Chemotherapy Full potential was recognized in the
More informationBreastCancerAdvisor by DR. SILVANA MARTINO AUGUST 2011
Dear Readers, It has been my privilege to work in the field of breast cancer for the past 32 years. Many changes have occurred during that time. The sum of these changes has been the diagnosis of breast
More informationESMO Breast Cancer Preceptorship Singapore November Special Issues in Treatment of Young Women with Breast Cancer
ESMO Breast Cancer Preceptorship Singapore November 2017 Special Issues in Treatment of Young Women with Breast Cancer Prudence Francis MD Peter MacCallum Cancer Centre Melbourne, Australia Conflict of
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: 07.01.16 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More informationPersonalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc
1 Personalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc Safe Harbor Statement This presentation contains forward-looking statements within the meaning
More informationCOLORECTAL CANCER 44
COLORECTAL CANCER 44 Colorectal Cancer Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Stuart M. Lichtman, MD Memorial Sloan-Kettering Cancer Center Commack,
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationTHE ESMO INTERNATIONAL ANTINEOPLASTIC MEDICINES SURVEY: HOW AVAILABLE ARE THE WHO ESSENTIAL CANCER MEDICINES?
THE ESMO INTERNATIONAL ANTINEOPLASTIC MEDICINES SURVEY: HOW AVAILABLE ARE THE WHO ESSENTIAL CANCER MEDICINES? Alexandru ENIU, MD, PhD Chair, ESMO Global Policy Committee Department of Breast Tumors Cancer
More informationState of the Art in 2000 State of the Art today Gazing forward
2010 Buschke Lecture: The Relationship between Local Recurrence and Survival in Breast Cancer Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School
More informationBreast. Presentation Outline
Breast FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.02 Presentation Outline Overview Anatomy of Breast Multiple Primary
More informationBreast. FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.
Breast FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.02 Presentation Outline Overview Anatomy of Breast Multiple Primary
More informationDuctal Carcinoma-in-Situ: New Concepts and Controversies
Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationNewly diagnosed with metatastic disease: where do we go from here? Rick Michaelson Saint Barnabas Medical Center
Newly diagnosed with metatastic disease: where do we go from here? Rick Michaelson Saint Barnabas Medical Center A Diagnosis of Advanced Breast Cancer Leads To Many Immediate Questions How am I supposed
More informationSupplementary Online Content
Supplementary Online Content Rugo HS, Klein P, Melin SA, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA. doi:10.1001/jama.2016.21038 Additional
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationBreast Cancer. Metastatic NCCN GUIDELINES FOR PATIENTS Available online at NCCN.org/patients. Please complete. our online survey at
NCCN GUIDELINES FOR PATIENTS 2018 Please complete our online survey at NCCN.org/patients/survey Breast Cancer Metastatic Presented with support from: Available online at NCCN.org/patients Ü Metastatic
More informationDo we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD
Do we have to change our anti-cancer strategy in case of cardiac toxicity? Point of view of the oncologist Guy Jerusalem, MD, PhD CHU Sart Tilman Liège Anticancer therapy: cardiac toxicity New anticancer
More information